PROCTER & GAMBLE HEALTH L

The earnings call for Procter & Gamble Health Limited on June 18, 2026, highlighted the company's strong performance for the fiscal year 2025-2026, reporting sales of nearly ₹1400 crore, a 16% increase year-over-year, and a profit after tax of ₹327 crores, up 30%. Management emphasized their integrated growth strategy, focusing on superior product offerings, effective communication, and enhanced retail execution. Key innovations included Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream, and Evion L5000, which have shown strong market adoption. The company also reported significant improvements in productivity, achieving ₹35 crores in savings. Management noted a robust engagement with healthcare professionals and a commitment to expanding their market reach, particularly in e-commerce and underserved areas. The call concluded with a Q&A session addressing various inquiries about product launches, market trends, and growth strategies.

Management emphasized strong growth and successful product innovations.